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Abstract  
Background  
Cardiac resynchronisation therapy (CRT) reduces morbidity and mortality in 
appropriately selected patients with heart failure and is strongly recommended for 
such patients by guidelines. An ESC CRT Survey conducted in 2008-09 showed 
considerable variation in guideline adherence and large individual, national and 
regional differences in patient selection, implantation practice and follow-up. 
Accordingly, two ESC associations, EHRA and the HFA designed a second 
prospective survey to describe contemporary clinical practice regarding CRT.   
 
Methods and Results  
A survey of the clinical practice of CRT-P and CRT-D implantation was conducted 
from October 2015 to December 2016 in 42 ESC member countries. Implanting 
centres provided information about their hospital and CRT service and were asked to 
complete a web-based case report form collecting information on patients’ 
characteristics, investigations, implantation procedures and complications during the 
index hospitalisation. 
 
The 11,088 patients enrolled represented 11% of the total number of expected 
implantations in participating countries during the survey period; 32% of patients 
were aged ≥75 years, 22% of procedures were upgrades from a permanent 
pacemaker or implantable cardiac defibrillator and 30% were CRT-P rather than 
CRT-D. Most patients (88%) had a QRS duration ≥130ms, 73% had LBBB and 26% 
were in atrial fibrillation at the time of implantation. Large geographical variations in 
clinical practice were observed. 
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Conclusion   
CRT Survey II provides a valuable source of information on contemporary clinical 
practice with respect to CRT implantation in a large sample of ESC member states. 
The Survey permits assessment of guideline adherence and demonstrates variations 
in patient selection, management, implantation procedure and follow-up strategy. 
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Introduction  
Randomised controlled trials (RCTs) and meta-analyses have demonstrated that 
Cardiac Resynchronisation Therapy (CRT) reduces morbidity and mortality in 
appropriately selected patients with symptomatic heart failure (HF), reduced left 
ventricular ejection fraction (LVEF) and QRS prolongation on the electrocardiogram. 
1-7 Accordingly, the benefits of CRT for such patients were accorded high levels of 
evidence and strong recommendations in European Society of Cardiology (ESC) and 
other international guidelines. 8-12 
 
The first ESC CRT Survey, performed in 2008-09 in 13 ESC countries, demonstrated 
that implanters often extrapolated the benefits of CRT to a broader population 
including patient groups that were not well represented in RCTs: such as patients 
aged >75 years or with a QRS duration <120 ms, atrial fibrillation (AF) or requiring an 
upgrade from an existing permanent pacemaker (PPM) or implantable cardiac 
defibrillator (ICD). The first CRT Survey also showed considerable regional and 
national differences in implantation practices. 13  Since this Survey was published, 
several important modifications of ESC Guideline recommendations concerning CRT 
indications have been made by both the Heart Failure Association (HFA) and 
European Heart Rhythm Association (EHRA).8, 9, 12 Therefore, these two ESC 
Associations decided to collaborate and undertake a pan-European Survey designed 
to describe current clinical practice regarding implantation of CRT devices in a larger 
sample of patients and greater number of ESC member countries. CRT Survey II was 
not designed to compare results with the first Survey. There was limited overlap 
between the cohorts of the two Surveys and substantial differences in the data 
collected precluding valid comparison. Lessons learned from conducting the first 
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Survey were used to improve both the design and performance of CRT Survey II, 
which involved many more countries.  CRT Survey II provides insights into 
contemporary clinical practice that is useful for patients, clinicians, administrators, the 
pharmaceutical and device industry as well as for parties who fund healthcare. 
Further analyses confined to the subset of countries participating in both surveys are 
planned. 
 
Methods  
Survey Infrastructure  
The Survey was designed as a joint initiative between EHRA and the HFA. These 
two ESC Associations co-coordinated the Survey with sponsorship from all five 
companies that manufacture CRT devices as well as from several pharmaceutical 
and diagnostic companies (see acknowledgements). The design and rationale of 
CRT Survey II, along with the detailed contents of the electronic case report form 
(eCRF) have been published previously. 14  
 
A Scientific Committee (SC) was established, composed of equal number of 
members from each Association, together with non-voting representatives from each 
of the five CRT device companies. The SC regularly monitored the progress of the 
Survey and agreed on logistical adjustments during the period of data collection.  
 
Recruitment 
The 47 ESC member states detailed in the 2014 EHRA White Book, which provided 
information on the number of sites implanting CRT and volume of activity in these 
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countries, were invited to participate.15 Each participating ESC member country was 
represented by a National Coordinator (NC) who was nominated by the President of 
their National Cardiology Society. The NCs were responsible for obtaining national 
Institutional Review Board (IRB) approval if required, recruiting centres in their 
country and distributing information from the Scientific Committee (SC) to their 
implanters. Of the 47 invited ESC member countries 42 agreed to participate. The 
NCs were requested to contact CRT implanters in their countries and invite them to 
participate in the Survey. Sites were then asked to enter consecutive patients 
implanted with a CRT during the inclusion period. 288 individual centres participated 
in CRT Survey II. 
 
Data collection, management and analyses  
For the first ESC CRT Survey, the web-based eCRF used for data collection was 
developed by Institut für Herzinfarktforschung Ludwigshafen (IHF). 16 They also 
conducted data-management and statistical analyses. Therefore, the Associations 
decided that IHF should support similar functions for CRT Survey II. Together with 
the SC, the IHF revised the eCRF, developed the statistical analysis plan and was 
responsible for data-monitoring and verification. No imputation for missing data was 
done. All percentages are relative to the total number of patients with available 
information.  
Each participating country had their data-points collected in the eCRF benchmarked 
against the total cohort. The day-to-day operational running of the Survey was 
conducted by Tessa Baak at Stavanger University Hospital, University of Bergen, 
Norway. 
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Survey population  
Any patient in the 42 participating countries was eligible for inclusion if he/she was 
implanted with either a CRT with pacemaker function (CRT-P) or a CRT with an 
incorporated defibrillator (CRT-D). This included both successful and un-successful 
implantations as well as both de-novo CRT devices and upgrades from a PPM or 
ICD.  Generator replacements or revisions of existing CRT devices were excluded as 
the Survey was designed to capture only new CRT implantations.  
 
The One-time Site Questionnaire  
Each implanting centre was requested to complete a one-time site questionnaire, 
which provided information on hospital type, size, population served, operator 
speciality, infrastructure, facilities and implantation routines for their CRT device 
programme. The data collected also provided useful information related to health-
care resource utilisation. 14  
 
The electronic case report form (eCRF) 
Implanting centres were asked to complete a web-based eCRF of consecutive 
patients scheduled to receive a CRT device. The eCRF collected information on 
patients’ characteristics, investigations, indications for CRT, implant procedures and 
short-term outcomes including adverse events and complications during the index 
hospitalization 14. Information on longer-term outcome was not collected. The eCRF 
was reviewed by ESC data-protection consultants to ensure patient anonymity. This, 
together with the fact that the Survey did not include follow-up data after discharge, 
obviated the necessity for formal IRB approval in most countries. Most centres were 
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simply required to notify their local or national ethical committee of their participation 
in the Survey.  
 
Timelines  
The first patient was included on October 1, 2015. The Survey was initially planned to 
run for 9 months. However, the SC decided to extend the enrolment by 6 months to 
December 31, 2016 in order to increase sample size and improve representativeness 
and therefore the ability to compare differences in practice amongst participating 
countries.   
 
Results 
The CRT Survey II recruited 11,088 patients from 42 ESC countries. The number of 
patients included per country is shown in Table 1. Using data from the EHRA White 
Book 2015 on national implantation rates we estimated representativeness, 17 that is, 
the number of patients enrolled compared with expected total implants in that 
country. This metric was updated continuously and permitted us to estimate how 
representative of the predicted national implantation rates was the data collected in 
the Survey.  
 
Overall, the Survey collected data on 11% of expected implantations during the 
enrolment period of the Survey. Of the 42 countries, 34 (81%) had >10% of the 
expected total number of implants for that country. 
 
Table 2-6 report key findings from the total cohort and the number of patients 
contributing to each data-point.  
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Hospital demographics (Table 2) 
University hospitals accounted for 59% of participating centres. The median 
(Interquartile range, IQR) number of CRT implants per hospital per year was 52 (30-
96) and 76% of centres were participating in a national device registry. Device 
remote monitoring was employed by 59% of centres and 99% of centres had either 
partial or total reimbursement from public health providers.  
 
Patient Characteristics (Table 3) 
The median (IQR) age at implantation was 70 (62-76), 32% of patients were aged 
≥75 years and 24% were women. Half of the patients had ischaemic heart disease, 
41% had a prior history of AF of which 42% of these were permanent AF, 31% had 
diabetes mellitus and 47% had a HF hospitalization during the previous year.   
 
Pre-implantation clinical evaluation (Table 4) 
Most patients were in New York Heart Association (NYHA) functional class III or IV 
(60%) and the natriuretic peptide levels were generally substantially elevated. The 
ECG at the time of implantation showed AF in 26%, a QRS duration of <130ms in 
13% and >150ms in 69% of patients and 73% had LBBB. On imaging, 28% of 
patients had an LVEF >35%, the median (IQR) LV end-diastolic diameter was 63 (58-
69) mm and 34% had either moderate or severe mitral regurgitation. The clinical 
indication for CRT implantation was HF with a wide QRS in 60% of cases, HF or LV 
dysfunction and indication for an ICD in 48%. In 10% of patients the sole clinical 
indication for CRT was HF and a PPM indication with expected RV pacing 
dependence.  
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CRT Implantation procedure (Table 5) 
Hospital admission was elective for 77% of implants, 77% of which were performed 
by electrophysiologists; 97% of procedures were successful, 70% of devices 
implanted were CRT-D and only 25% were referrals from other centres.  The median 
duration of the procedure (IQR) was 90 (65-120) minutes. The RV lead was 
implanted first in 84% of cases and the LV lead was multipolar in 57%. The LV 
position was evaluated by biplane X-ray projection in 88% of patients. The left 
anterior oblique site was lateral in 84% and the right anterior oblique site was middle 
in 71%. The peri-procedural complication rate was 6%. The most common 
complications were coronary sinus dissection, bleeding and pneumothorax.  
 
Post CRT Implantation data (Table 6).   
The median (IQR) hospital stay was 3 (2-7) days. In 5% of patients an adverse event 
was reported and 0.4% died during the index hospitalization. Follow up was planned 
at the implanting centre in 86% of patients. AV programming was performed prior to 
discharge in 58% and VV programming in 56% of patients.  Device-based software 
was used to optimize programming in 36%.  Heart failure medications at discharge 
included loop diuretics (81%), β -blockers (89%), angiotensin converting enzyme 
(ACE) inhibitors or angiotensin receptor blockers (ARBs) (86%) and mineralocorticoid 
receptor antagonists (MRAs) (63%). Overall, 47% of patients were anticoagulated, 
mostly (70%) with warfarin; 10% of anticoagulated patients had no history of AF.    
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Benchmarking the top 10 recruiting countries (Figure 1; Panels A-G) 
Data from the 10 countries that enrolled the most patients were compared.  
There were substantial differences amongst countries in the mean age of patients 
implanted (Panel A). The symptom severity varied substantially amongst countries 
(Panel B). The proportion of patients with AF was about 26% with a range of 16 to 
29%. In all countries, most patients had LBBB but this ranged from as low as 61 to 
82% (Panel C). The percentage of patients with a QRS duration <130 ms ranged 
from 7 to 19% but most patients had a QRS duration >150 ms (panel D). The 
percentage of patients upgraded from another device was between 21 to 39% (Panel 
E) and those receiving a CRT-P ranged from 2 to 37% (Panel F). The median 
duration of hospitalization varied markedly (Panel G), with a median of 3 days.  
 
Discussion  
This second, larger survey of CRT implantations in ESC member countries provides 
a valuable source of clinical information describing ‘who is doing what to whom and 
how’, permits benchmarking across Europe and provides essential feedback on 
guideline adherence, which supports the development of future guidelines.  
The ‘Who’ are implanters, and as expected, primarily electrophysiologists, although a 
considerable number of implanters are not (23%). The ‘What’ are primarily CRT-D 
devices (70%) but in many countries up to 40% of implants are CRT-P devices. The 
‘Whom’ (patients selected for CRT implantation) are predominantly men, <75 years, 
with an LVEF <35%, in sinus rhythm, with LBBB and a QRS duration ≥150ms. The 
‘How’ reveals that most implantations are elective with a low peri-procedural mortality 
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(<1%). Referrals from non-implanting centres accounted for only 25%, indicating that 
patients outside university or teaching hospital settings have limited access to CRT.  
The Swedish HF Registry, which included 12,807 patients, demonstrated that 
underutilization was associated with demographic, organizational and socio-
economic characteristics as well as clinical information. For example, the likelihood of 
being considered for CRT was much higher if the patients were managed by 
cardiologists rather than other specialists or primary care physicians.18 
An excellent overview of the diverse issues that serve to explain why only about one-
third of CRT candidates are actually implanted with a device has recently been 
published. 19 CRT Survey II also confirms that clinicians continue to extrapolate data 
from RCTs to patients who are not well represented in the evidence base. Clinical 
practice may be guided by clinical trials but differences in practice exist because 
clinicians have accumulated experience and try to offer the best treatment to 
individual patients, many of whom do not fulfil the selection criteria for the RCTs. 
Many devices were implanted in patients, with AF or relatively narrow QRS 
complexes, or requiring a device upgrade. In these patient groups, guidelines either 
contra-indicate CRT or make only weak recommendations. Compared  to patients 
enrolled in RCTs, patients in this Survey were generally older,  had more 
comorbidities, were less likely to have ischaemic heart disease, had higher LVEF, 
narrower QRS complexes and more AF but a similar proportion were women. 20  
Compared to men, the low number of women receiving CRT is of concern. Women 
with HF with reduced ejection fraction (HFrEF) are more likely to have LBBB and may 
benefit from CRT at a shorter QRS duration than men. 21, 22 However, women with 
heart failure are older and less likely to have a reduced EF.23  Accordingly, the low 
number of women receiving CRT may reflect the relatively lower number of women 
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aged <75 years with HFrEF rather than a lower proportion of such women who are 
eligible for CRT.  
CRT implants were upgrades from a previous PPM or ICD device in 28% of 
procedures. The landmark trials of CRT, with the exception of RAFT, excluded 
patients with a prior device. In RAFT an upgrade from an ICD or PPM was not 
associated with benefit. 7 Accordingly, the 2012 HFA Guidelines do not provide 
guidance on upgrades. Although the ESC EHRA 2013 Guidelines provided a Class I 
recommendation level of evidence B for device upgrade for patients with persistent 
symptoms compatible with heart failure  9  the 2016 HFA Guidelines offered only a 
Class IIb recommendation. 8 Although a pacing generally prolongs QRS duration, its 
clinical significance with respect to CRT may differ. The importance of atrio-
ventricular resynchronization may be as or more important than bi-ventricular 
resynchronization and the benefit of upgrading devices to CRT is not well 
established.   
The rhythm at implantation was AF for 26% patients in this survey. The EHRA 2013 
and HFA 2012 and 2016 guidelines provide either a IIa or IIb recommendation for 
patients with AF but emphasise the importance of pharmacological rate control or AV 
nodal ablation in order to adequate ensure bi-ventricular capture. 8, 9, 12 No 
substantial trial has compared CRT to a pharmacological control group for patients 
with AF. A subgroup of patients in the RAFT study had AF and did not appear to 
benefit, which was ascribed to inadequate ventricular capture. 7 Similarly, a recent 
report from COMPANION also suggested that patients with a prior history of AF did 
not benefit from CRT, although incident AF did not appear to reduce benefit in CARE-
HF 4, 24. At least two trials have compared CRT to RV pacing after AV node ablation. 
These suggest that CRT is superior. 25, 26 However, whether this reflects a benefit 
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from CRT or simply avoiding the harm of RV pacing is unclear. For this reason, some 
experts think that current guidelines provide an unduly strong recommendation for 
CRT in patients with AF.  
This Survey shows that 8% of implants were in patients with a QRS <120 ms and 
that a further 5% had a QRS duration 120-129ms. The HFA 2012 Guidelines 
recommended CRT implantation only when QRS duration was >120 ms in the 
presence of more severe symptoms and LBBB, >130ms when symptoms were mild 
and LBBB was present or when QRS duration was >150ms in the absence of LBBB. 
12 In May 2016 the most recent version of the HFA Guidelines, based on the results 
of ECHO-CRT and an individual-patient data (IPD) meta-analysis, suggested that 
CRT is contra- indicated when QRS duration is <130ms. 8, 27-29 This Survey ran from 
October 2015 to December 2016. Future analyses will determine whether practice 
evolved over the course of the survey. 9, 12  Of note, the median QRS duration was 
narrower (144 ms compared with 160 ms) for patients implanted only for the clinical 
indication ‘PM indicated and expected RV pacing dependence’ compared to the 
overall cohort. 10% of the Survey population were implanted with only this clinical 
indication and 22% of this group had a QRS duration <120 ms. However, most 
patients in this Survey had a QRS duration ≥150 ms. IPD meta-analyses of RCTs 
have convincingly shown that longer QRS durations predict greater long-term benefit 
from CRT. 28, 30 
Patients in this Survey were generally treated with loop diuretics (81%), ACE 
inhibitors / ARBs (86%), β-blockers (89%), and MRAs (63%) at discharge from 
hospital. Guidelines recommend implantation of CRT only after patients have been 
optimally medically managed. Although the proportion of patients in the Survey 
discharged on disease-modifying medications is less than ideal and less than 
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observed in some registries, it is still similar or greater than observed in most of the 
landmark clinical trials that proved the efficacy of CRT, many other registries or in 
clinical practice.18, 31   
The process of developing evidence-based guidelines includes both adequate 
evaluation by randomised clinical trials as well as feedback from surveys and 
registries. Survey and registries demonstrate the degree to which guidelines are 
adopted in practice. Therefore, the extensive observational data that we have 
collected highlights both which guideline recommendation are or are not being 
adhered to as well as how physicians extrapolate existing data to clinical challenges 
they encounter in practice where evidence is lacking. These gaps in evidence are 
intentionally included in all ESC guidelines in order to identify potentially fruitful area 
for future research.  
The one-time site questionnaire included information such as total number of beds 
per hospital, type of hospital, number of CRT devices implanted annually and the 
number and speciality of implanters, which provides valuable information related to 
health care resource demands and capacity. A dedicated health care resource 
utilization paper will be published.  
The data selected for benchmarking is directly related to patient selection, clinical 
practice and health care resource utilization in the top 10 recruiting countries. 
Benchmarking of these countries in the Survey revealed remarkable similarities with 
regards to patient selection.  However, there were also many highly significant 
differences between countries (Figure 1) especially the populations aged ≥ 75 years 
with QRS <130 ms,  NYHA Class III or IV as well as choice of device (CRT-P vs 
CRT-D).   
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Particularly striking was the difference in index hospitalization duration between the 
top 10 countries.  Hospitalization for implantation of a CRT can facilitate initiation and 
up-titration of optimal medical therapy, which can prolong hospital stay. Differences in 
the length of hospital stay depend both on the implanting centre and the collaboration 
with the outpatient HF services.  Some of the observed differences in these countries’ 
CRT implantation practice will be related to the country’s economic strength, the 
proportion of their budget allocated to healthcare and the demographics of the 
population. The initial cost of CRT is substantial due to the device itself, the 
implantation procedure, hospitalisation and follow-up. However, the symptomatic 
improvement following CRT and the reduction in HF hospitalization makes it an 
effective use of resources. Countries with limited financial resources may select  
patients most likely to respond and also may prefer CRT-P to CRT-D due to the 
reduced cost. In Europe, physicians may be more willing to extrapolate beyond the 
existing evidence and guidelines for CRT because the risk of medical litigation is 
relatively low. Most procedures are funded partly or entirely by public funding and 
there is limited formal audit of adherence to guidelines. 
 
 
Limitations  
The strength and ability of a survey to address questions are related to the strength 
of its methodology, its representativeness and size. Although the number of patients 
enrolled in this Survey was large, there were substantial differences amongst 
countries. Overall, we estimate that about 11% of patients implanted with CRT in 
participating countries were enrolled in the Survey. We cannot assess the degree of 
selection bias in the choice of enrolled patients. Sites may have been less likely to 
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report unsuccessful implants or cases with a poor outcome, accounting for low 
complication and mortality rates. The number of implanting sites ranged from 1 to 37. 
In countries with few participating centres, these centres’ practice will have a great 
impact on the national results.    
 
The eCRF was designed to be as user-friendly as possible in order to maximise the 
number of patients enrolled. Unavailable patient data could be omitted; the analyses 
were based on the available data, which explains the variation in the sample size for 
each data point.  Furthermore, the interpretation of questions was up to the discretion 
of the investigator. Although there was no formal independent monitoring of the data 
collection, the IHF conducted ‘front-end’ data check and post database lock quality 
control analyses designed to prevent incorrect data being analysed. The most recent 
ESC HF Guidelines were released during the enrolment period of the Survey.8 It 
requires time before new guidelines are adopted into evolving clinical practice. It is 
difficult to quantify the effect that this had on the selection and enrolment of patients 
subsequent to the release of the most recent ESC Guidelines. 
 
 
Conclusion   
CRT Survey II provides a valuable source of information on contemporary clinical 
practice with respect to CRT implantation in a large sample of ESC member states. 
The Survey demonstrates important similarities as well as substantial differences in 
patient selection, implantation procedure and follow-up. The data collected are 
sufficient to permit meaningful benchmarking between the highest recruiting countries 
and for assessing guideline adherence and healthcare resource utilisation. This 
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should assist in educational initiatives and identifying appropriate directions for future 
research.  
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Legend Figure 1  
 
Asterisks demonstrate the level of statistical significance of the bottom red category 
for each country as compared to the total cohort. One asterisk denotes a p-value of 
<0.01 and two asterisks a p-value <0.001. 
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Table 1 CRT Survey II Total Cohort 
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Table 2 Hospital Demographics  
Hospital Demographics  n =288 
Inhabitants of area median (in 100.000) (IQR) 5 (3-10) 
Total number of hospital beds median (IQR) 600 (357-964) 
Number of cardiology beds median (IQR) 57 (34-80) 
Type of hospital    
University hospital  59 % (162/274) 
Teaching hospital (non-university) 23 % (64/274) 
Community hospital 10 % (27/274) 
Private hospital 8 % (21/274) 
CRT implantations per year median (IQR) 52 (30-96) 
Pacemaker implantations per year median (IQR)  250 (175-400) 
ICD implantations per year median (IQR) 80 (40-132) 
Cardiac surgery on site   69 % (190/274) 
Angiography/PCI on site   96 % (262/273) 
Dedicated electrophysiological labs median(IQR)  1 (1-2) 
Number of CRT implanters median (IQR)   
Electrophysiologists   2 (1-4) 
Interventional cardiologists   0 (0-4) 
Heart failure physicians  0 (1-2)  
Follow-Up     
Implanting centre 93 % (254/272) 
Heart failure clinic 68 % (186/273) 
Dedicated CRT clinic 59 % (161/273) 
Remote device monitoring service 70 % (191/272) 
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Centre uses device monitoring by telemetry    59 % (169/288) 
Dedicated lead extraction/management program  45 % (123/272) 
Participation in a national device registry  76 % (207/273) 
Use electronic medical health records  81 % (221/273) 
Source of reimbursement for CRT    
Public health provider 99 % (270/274) 
Private insurance 12 % (32/274) 
Private payer 7 % (20/274) 
 
IQR – interquartile range, CRT – Cardiac Resynchronization therapy, ICD- Implantable cardiac 
defibrillator, PCI –percutaneous coronary intervention. In parenthesis, we indicated the number of 
centres in each category compared to the total cohort for each data-point. 
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Table 3 Patient Demographics  
Demographic   n=11088 
Age median (years) (IQR)  70 (62-76) 
Age >=75   32 % (3536/11039) 
 Female   24 % (2686/11052) 
Primary HF aetiology   
 Ischaemic  45 % (4875/10953) 
Non-ischaemic  55 % (6078/10953) 
Past history and major comorbidity   
 Previous myocardial infarction   36 % (3957/10926) 
Prior revascularization (PCI/CABG)   39 % (4245/10924) 
Hypertension   64 % (6962/10900) 
Atrial fibrillation   41 % (4459/10920) 
Valvular heart disease   27 % (2968/10920) 
Obstructive lung disease   12 % (1315/10922) 
Diabetes   31 % (3428/10921) 
Anaemia   15 % (1640/10916) 
Chronic kidney disease (eGFR <60)   31 % (3395/10907) 
Previous device (PPM or ICD)   22 %(2434/10992) 
HF hospitalization during past year   47 % (5078/10917)  
Currently enrolled in a clinical trial   8 % (918/11028) 
 
 
IQR – interquartile range, PCI –percutaneous coronary intervention, CABG- coronary artery bypass 
grafting, eGFR –estimated glomerular filtration rate, PPM –permanent pacemaker, ICD –implantable 
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cardiac defibrillator, HF- heart failure. In parenthesis, we indicated the number of patients in each 
category compared to the total cohort for each data-point. 
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Table 4 Pre-implant clinical evaluation  
 
Pre-implant clinical evaluation   n=11088 
NYHA class    
I 3 % (370/10848) 
II 38 % (4083/10848) 
III 55 % (5909/10848) 
IV 5 % (486/10848) 
BMI median (kg/m²)  (IQR) 27 (25-31) 
Systolic blood pressure median (mmHg) (IQR)   122 (110-137) 
Diastolic blood pressure median (mmHg) (IQR) 72 (66-80) 
Laboratory measurement  median (most recent) (IQR) 
 BNP (ng/L) 422 (150-1115) 
NT-proBNP (ng/)   2400 (1049-5517) 
Serum Creatinine (μmol/l)  100 (83-129) 
Haemoglobin (g/dl) 13 (12-15) 
Pre-implant ECG   
Heart rate median bpm (IQR)  70 (60-80) 
Atrial rhythm    
Sinus 69 % (7496/10836) 
Atrial fibrillation 26 % (2778/10836) 
Atrial paced 3 % (303/10836) 
Other 2 % (259/10836) 
PR interval median (IQR) (ms)  180 (160-210)   
AV block II/III  19 % (2026/10700) 
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Pacemaker dependant  14 % (1511/10752) 
Intrinsic QRS morphology    
LBBB 73 % (7861 /10800) 
Non LBBB 27 % (2939 /10800) 
Intrinsic QRS duration  
         Median (IQR) 160 (140 -174)  
 < 120 ms  8 % (711/9535) 
120 -129 ms  5 % (505/9535) 
130 -149 ms 19 % (1779/9535) 
150 -179 ms  47 % (4486/9535) 
>180 ms  22 % (2054/9535) 
Clinical indication for CRT    
HF with wide QRS 60 % (6550/10923) 
HF or LV dysfunction and indication for ICD 48 % (5228/10923) 
PM indication and expected RV pacing dependence 23 % (2494/10923) 
Evidence of mechanical dyssynchrony 12 % (1260/10923) 
Other 5 % (487/10923) 
LVEF   
         Median  (IQR) 29 (23-34) 
LVEF <25  28 % (2979/10805) 
LVEF 25 -35%  60 % (6426/10805) 
LVEF >35 %  13 % (1400/10805) 
LVEDD  median (IQR) (mm) 63 (58-69) 
Mitral regurgitation      
Mild 46 % (4644/10000) 
Moderate 27 % (2646/10000) 
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Severe 7 % (690/10000) 
None 20 % (2020/10000) 
 
NYHA – New Year Heart Association, BMI- body mass index, IQR- interquartile range, BNP –brain 
natriuretic peptide, NT pro-BNP- N-terminal pro BNP, bpm- beats per minute, LBBB –left bundle 
branch block, CRT – Cardiac Resynchronization Therapy, HF- heart failure, LV- left ventricle, ICD –
implantable cardiac defibrillator , PM –pacemaker, RV- right ventricular, EF- ejection fraction. Note: 
total can = > 100% due to rounding off. In parenthesis, we indicated the number of patients in each 
category compared to the total cohort for each data-point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
Table 5, CRT Implantation Procedure 
 
CRT Implantation Procedure  n= 11088 
Elective admission   77 % (8422/10946) 
Referral from another centre   25 % (2770/10938) 
Admission to implantation time median (IQR) (day) 1 (1-4) 
Successful implantation   97 % (10798/11100) 
Non-successful implantation   3 % (302/11100) 
Number of attempts per patient   
      One attempt per patient 99 % (10971/11088) 
      Two attempts per patient 1 % (106/11088) 
      Three attempts per patient <1% (11/11088) 
Type of device   
 CRT-P 30 % (3256/10769) 
CRT-D 70 % (7513/10769) 
Operator  
 Electrophysiologist 77 % (8302/10779) 
HF physician 5 % (541/10779) 
Invasive cardiologist 12 % (1330/10779) 
Surgeon 4 % (464/10779) 
Other 1 % (142/10779) 
Duration of procedure, median (min) (IQR)  90 (65-120) 
Fluoroscopy time, median (min) (IQR)  14 (8-22) 
Prophylactic antibiotics   99 % (10527/10672) 
Which lead was implanted first   
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RV 84 % (8816/10555) 
LV 16 % (1733/10555) 
RV lead placement   
 Apex 61 % (6280/10253) 
Septum 36 % (3733/10253) 
RVOT 2 % (240/10253) 
LV lead placement successful   99 % (10533/10594) 
LV lead type   
 Unipolar 1 % (77/10601) 
Bipolar 42 % (4478/10601) 
Multipolar 57 % (6046/10601) 
Coronary venogram performed   92 % (9636/10529) 
Venogram performed with occlusion   47 % (4486/9522) 
Dilatation of coronary vein performed   2 % (251/10538) 
Phrenic nerve stimulation tested   90 % (9556/10568) 
LV lead position evaluation   97 % (9943/10302) 
Biplane x-ray projection   88 % (8771/9943) 
Monoplane LAO 11 % (1105/9943) 
Monoplane RAO 1 % (67/9943) 
LAO site    
 Lateral 84 % (8665/10300) 
Posterior 12 % (1188/10300) 
Anterior 4 % (447/10300) 
RAO site   
 Middle 71 % (7200/10119) 
Basal 15 % (1505/10119) 
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Apical 14 % (1414/10119) 
LV position optimized   34 % (3484/10307) 
Peri-procedural complications  6 % (624/11088) 
Death   0.1 % (8/11088) 
Bleeding 1.0 %  (108/11088) 
Bleeding requiring intervention 0.3 % (35/11088) 
Pocket hematoma 0.8 % (85/11088) 
Pneumothorax 1.0 % (112/11088) 
Haemothorax 0.1 %  (9/11088) 
Coronary sinus dissection  1.9 % (214/11088) 
Pericardial tamponade 0.3%(28/11088) 
Other 1.6 % (172/11088) 
 
CRT – Cardiac Resynchronization Therapy, IQR – interquartile range, P-pacemaker, D-defibrillator, HF 
–heart failure, RV- right ventricle, LV – left ventricle, RVOT –right ventricular outflow tract, LAO – left 
anterior oblique, RAO –right anterior oblique. Note: total can = > 100% due to rounding off. In 
parenthesis, we indicated the number of patients in each category compared to the total cohort for 
each data-point. 
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Table 6 Post CRT Implantation  
 
Post CRT Implantation  n=11088 
Post-implant ECG 
 Paced QRS duration median (ms) (IQR)  137 (120-151) 
Device programming  
 AV programming performed prior to discharge  58 % (6132/10593) 
VV programming performed prior to discharge  56 % (5962/10577) 
Device-based software optimization for AV or VV  36 % (3821/10500) 
Discharge status   
 Alive 99.6 % (10801/10845) 
Dead 0.1%  (45/10845) 
Total length of hospital stay median (days) (IQR)  3 (2-7)  
Major adverse events after Implantation   5 % (528/11088) 
Myocardial Infarction  0.1 % (8/10816) 
Stroke 0.1 % (6/10816) 
Infection 0.6 % (60/10816) 
Worsening heart failure  0.7 % (78/10816) 
Worsening renal function 1.0% (104/10816) 
Arrhythmias 1.2 % (128/10816) 
Other 1.9 % (208/10816) 
Planned Follow-Up  
 Implanting centre 86 % (9345/10818) 
Other hospital 8 % (873/10818) 
Cardiologist in private practice 5 % (569/10818) 
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Primary care physician 1 % (92/10818) 
CRT/ pacemaker clinic 10 % (1124/10818) 
Heart failure management clinic 3 % (273/10818) 
Other 0 % (34/10818) 
Drug therapy at discharge  
 Loop diuretic  81 % (8621/10635) 
ACE inhibitor/ARB 86 % (9163/10603) 
MRA (aldosterone antagonist)  63 % (6682/10573) 
β-blocker  89 % (9472/10648) 
Ivabradine  6 % (593/10543) 
Digoxin  10 % (1100/10544) 
Calcium channel blocker  9 % (946/10531) 
Amiodarone  17 % (1825/10547) 
Other anti-arrhythmic agent  2 % (181/10531) 
Oral anticoagulant  47 % (4928/10577) 
Warfarin (Coumadin)  33 % (3463/10577) 
Dabigatran 3 % (327/10577) 
Rivaroxaban 6 % (611/10577) 
Apixaban 5 % (509/10577) 
Edoxaban <1 % (18/10577) 
Anti-platelet agent    44 % (4846/11088) 
Aspirin 41 % (4357/10547) 
Clopidogrel 12 % (1304/10547) 
Ticagrelor 1 % (136/10547) 
Prasugrel <1 % (31/10547) 
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ECG- electrocardiogram, IQR -interquartile range, AV –atrioventricular, VV-ventriculo-ventricular, 
CRT- Cardiac Resynchronization Therapy, ACE –angiotensin enzyme, ARB –angiotensin II receptor 
blocker, MRA- mineralocorticoid receptor antagonist. In parenthesis, we indicated the number of 
patients in each category compared to the total cohort for each data-point. 
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Figure 1, Panel A - Age of Patients Implanted with CRT by Countries  
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Figure 1, Panel B - NYHA Classification across Countries  
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Figure 1, Panel C - QRS Morphology on Pre-Implantation ECG per Country.  
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Figure 1, Panel D - QRS Duration on Pre-implantation ECG per Countries  
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Figure 1, Panel E - Upgrades to CRT from Previous device (PPM or ICD) per Country  
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Figure 1, Panel F - Type of Device Implanted (CRT-P vs. CRT-D) per Country 
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Figure 1, Panel G - Length of Hospital Stay per Country.  
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